Mbx Biosciences
Clinical trials sponsored by Mbx Biosciences, explained in plain language.
Biotech developing peptide therapies for endocrine and metabolic disorders.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New shot aims to stop dangerous sugar crashes after gastric bypass
Disease control CompletedThis study tests a new drug called MBX 1416 in 10 people who have low blood sugar episodes after weight loss surgery. Participants receive two injections of the drug, a low dose and a high dose, about two weeks apart. The goal is to see if the drug can raise the lowest blood suga…
Phase: PHASE2 • Sponsor: MBX Biosciences • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Weekly shot could cut calcium pills for rare hormone disorder
Disease control CompletedThis study tested a new medicine called MBX 2109, given once a week as a shot, in 64 adults with hypoparathyroidism. The goal was to see if it could safely help patients reduce their daily calcium and vitamin D pills while keeping blood calcium levels normal. The trial was comple…
Phase: PHASE2 • Sponsor: MBX Biosciences • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Kidney function key to new Drug's safety
Knowledge-focused CompletedThis study looked at how the experimental drug MBX 2109 is handled by the body in people with different levels of kidney function. 25 adults with normal or impaired kidneys received a single dose. The goal was to measure safety and drug levels, not to treat a disease. Results wil…
Phase: PHASE1 • Sponsor: MBX Biosciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC